However, while the heterogeneity of MS may challenge the discovery of neuron-specific autoantigens and autoreactive effector CD8+ T cells, this same variability also suggests that a specific subset of MS patients — perhaps those with certain primary or secondary progressive features — may harbor pathogenic neuronal antigen–specific T cells. Here, CD8A is linked to myeloid sarcoma.